factual

Conflicted Votes Kept COX-2 Drugs on Market

At the 2005 FDA advisory hearings on COX-2 inhibitors, 10 of the 32 committee members had financial ties to Merck or Pfizer, and had those conflicted votes been discounted, all the drugs except a black-box-warned Celebrex would have been removed from the market.

factualpending

Speaker

Marcia Angell

Evidence Quote

“Ten of the 32 had financial conflicts of interest. And if those votes had been discounted, all of those drugs would be taken off the market except for Celebrex”

Source

Marcia Angell on Big Pharma— EconTalk
Created: 6/13/2026, 12:08:22 AM

Your notes

Loading notes...